Please try another search
For the nine months ended 30 September 2014,Calipharms Inc revenues increased from $0K to $112K. Netloss increased from $108K to $6.3M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects General and administrative expenses increase from$108K to $248K (expense), Interest expense - other increasefrom $0K to $5K (expense).
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Total Revenue | 1.08 | 0.34 | 0.02 | 0 |
Gross Profit | 1.08 | 0.34 | -0.01 | 0 |
Operating Income | -36.85 | -10.8 | -0.33 | -0.08 |
Net Income | -37.52 | -11.02 | -0.78 | -0.1 |
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Total Assets | 278.04 | 278.04 | 0.06 | 0.02 |
Total Liabilities | 91.75 | 91.75 | 3.54 | 2.76 |
Total Equity | 186.3 | 186.3 | -3.48 | -2.74 |
Period Ending: | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 17.91 | 17.91 | -0.25 | -0.04 |
Cash From Investing Activities | -27.41 | -27.41 | ||
Cash From Financing Activities | -2.42 | -2.42 | 0.27 | 0.04 |
Net Change in Cash | -11.91 | -11.91 | 0.02 | 0 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review